Wild-type transthyretin amyloidosis is an underdiagnosed condition that accounts for a significant proportion (13%) of HFpEF cases.
ATTRwt is an underdiagnosed disease that accounts for a significant number (13%) of HFpEF cases. The effect of emerging TTR-modifying drugs should be evaluated in these patients.
González-López et al. (Tue,) studied this question.